The Bureau of Pharma PSUs of India, which implements the Centre’s flagship affordable medicine scheme PMBJP, has found 25 batches of drugs of 18 different pharmaceutical companies to be of substandard quality since January 2018, according to an official document. While 17 out of the 18 companies are private, one is a public sector unit — Indian Drugs and Pharmaceuticals Limited, according to the document. Both the BPPI and the IDPL work under the Department of Pharmaceuticals of the central government. Batches of two drugs of AMR Pharma India Private Limited were found to be substandard by the bureau. Just like AMR Pharma, batches of two drugs of the following companies also- Modern Laboratories, Legen Healthcare, Ravian Life Science, Max chem Pharmaceuticals, Theon Pharmaceuticals, Mascot Health Series and Terrace Pharmaceuticals – were found to be substandard as revealed by the BPPI.